Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.

Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.

Item
http://www.wikidata.org/entity/Q38068584
Time-Based Switching Control of Genetic Regulatory Networks: Toward Sequential Drug Intake for Cancer Therapy.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancerThe Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
P2860

Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.

Item
http://www.wikidata.org/entity/Q38068584
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
@en
type
label
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
@en
prefLabel
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698